Key Information

• EU Funding: € 4.10 Million.
• Total budget: € 6.84 Million.
• Duration: 36 months [October 2018 – September 2021].

Aim

3DMed aims to improve the affordability and large-scale accessibility of medical treatment using 3D printed devices. Top universities and innovative companies in the Netherlands, Belgium, France and the UK join forces in an unprecedented exercise to explore the full potential of the 3D printing technology for advanced medical care.

Expected results

• Streamlined care by integrating diagnosis, design and manufacturing of 3D printed medical devices with post-operative evaluation into a validated and widely accessible software platform. This will enable reduction of lead times from 6-8 weeks currently to 6-8 days by 2021 and to 24 hours by 2023.
• Personalized medical devices (prostheses, implants and orthoses) designed using the images acquired for individual patients. Using the integrated 3D printing technology to manufacture these customised devices will lead to reductions in cost by as much as 90%. The costs for the medical treatments will thereby be decreased by as much as 30%.
• Complex shapes and miniaturized geometries for implants and surgical instruments, as well as functionalised medical devices to enhance treatment effectiveness and speed up post-treatment recovery.

Lead partner

• TU Delft

Project Partners

• 3D LifePrints
• Amber Implants B.V.
• Avroxa bvba (ULTROXA Polymers)
• Association pour la Recherche et le Développement des Méthodes et Processus Industriels
• Dutch Ophthalmic Research Center (International) B.V.
• EURASANTÉ
• EXO-L B.V.
• Meridian Technique Limited
• Oceanz B.V .
• Oxford MESTAR Limited
• Régnier Orthopédie
• Stichting Materials innovation institute
• Strategisch Initiatief Materialen
• Universiteit Gent
• Université de Lille
• University of Oxford